医学
非达霉素
随机对照试验
养生
内科学
临床终点
指南
万古霉素
腹泻
临床试验
抗生素
梭菌纲
外科
儿科
细菌
遗传学
金黄色葡萄球菌
病理
微生物学
生物
作者
Stuart Johnson,Dale N. Gerding,Xue Li,Domenic J. Reda,Curtis J. Donskey,Kalpana Gupta,Matthew Bidwell Goetz,Michael W. Climo,Fred M. Gordin,Robert K. Ringer,Neil F. Johnson,Michelle Johnson,Lawrence A. Calais,Alexa M Goldberg,Lan Ge,Tamara Haegerich
标识
DOI:10.1016/j.cct.2022.106756
摘要
Although many large, randomized controlled trials (RCT) have been conducted on antibiotic therapy for patients with primary C. difficile infections (CDI), few RCTs have been performed for patients with recurrent CDI (rCDI). In addition, fecal microbial transplant (FMT) is neither FDA-approved or guideline-recommended for patients with pauci-rCDI (first or second recurrences). Therefore, a rigorous RCT of sufficient size was designed to determine the optimal treatment among three antibiotic regimens in current practice for treatment of pauci-rCDI.VA Cooperative Studies Program (CSP) #596 is a prospective, double-blind, multi-center clinical trial of veteran patients with pauci-rCDI comparing fidaxomicin (FDX) 200 mg twice daily for 10 days and vancomycin (VAN) 125 mg four times daily for 10 days followed by a 3-week vancomycin taper and pulse (VAN-T/P) regimen to a standard course of VAN 125 mg four times daily for 10 days. The primary endpoint is sustained clinical response at day 59, with sustained response measured as a diarrhea composite outcome (D-COM) that includes symptom resolution during treatment (before day 10) without recurrence of diarrhea or other clinically important outcomes through day 59.CSP study 596 is designed to compare three current antibiotic treatments for recurrent CDI that are in clinical practice, but which lack high-quality evidence to support strong guideline recommendations. The design of the study which included a pilot phase initiated at six sites with expansion to 24 sites is described along with protocol modifications based on early trial experience and clinical realities including the COVID-19 pandemic.This study is registered with clinicaltrials.gov (Identifier: NCT02667418).
科研通智能强力驱动
Strongly Powered by AbleSci AI